Purple Book product · Reference 351(a)
ALTUVIIIO
antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl
Feb 22, 2023
Approved
Reference 351(a)
License type
Rx
Marketing
None
Listed patents
Sourced from the FDA Purple Book · verified Jul 02, 2026
Key dates
Orphan exclusivity ends
7-year orphan-drug exclusivity window.
Feb 22, 1930
97 yr 10 mo ago
Approval
Approval date of this BLA submission.
Feb 22, 2023
3 yr 5 mo ago
Today
Pharmaceutical detail
Strength
4000IU
Dosage form
For Injection
Route
Intravenous
Presentation
Single-Dose Vial
Center
CBER
License number
2078
Product number
007
Submission type
Original
Supplement number
0
Change type
Not listed
Reference product family
View full familyThis is the reference (originator) product. No biosimilars or interchangeables reference it in the Purple Book yet.
6 additional BLA records for this product (other strengths or presentations) are in the same reference family.
Patent list
No patent-list records were published for this product. The Purple Book patent list reflects the statutory patent exchange under the BPCIA and is not exhaustive.
Source provenance
- advanced-searchAdvanced Search · Jul 02, 2026
- monthly-downloadMonthly download · Jul 02, 2026
Change history
- v4Jul 02, 2026
- v3Jul 02, 2026
- v2Jul 02, 2026
Frequently asked questions
Does ALTUVIIIO have approved biosimilars?
No 351(k) biosimilars or interchangeable biosimilars referencing ALTUVIIIO are listed in the FDA Purple Book yet.
What is ALTUVIIIO's BLA number?
ALTUVIIIO is licensed under BLA 125771, held by Bioverativ Therapeutics, Inc..
When was ALTUVIIIO approved by the FDA?
ALTUVIIIO was approved by the FDA on Feb 22, 2023.
Related FDA reference tools
- FDA Orange BookApproved drugs, generics, therapeutic-equivalence codes, patents, and exclusivity.
- FDA BiosimilarsThe list of FDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 & Inspection DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
